Keros Therapeutics has announced an exclusive global licensing agreement with Takeda Pharmaceutical (TAK, Financial) to advance the development of elritercept. This drug is currently undergoing two Phase 2 clinical trials targeting patients with very low, low, or intermediate-risk myelodysplastic syndromes (MDS) and myelofibrosis (MF). A Phase 3 trial, RENEW, will soon begin recruiting patients to evaluate elritercept's efficacy in adult MDS patients who require transfusions.
Under the agreement, Takeda will have exclusive rights to further develop, manufacture, and commercialize elritercept worldwide, excluding mainland China, Hong Kong, and Macau. Keros will receive a $200 million upfront payment and may earn over $1.1 billion in milestone payments.
